Gary Lee's most recent trade in Lyell Immunopharma Inc was a trade of 1,671 Common Stock done at an average price of $23.4 . Disclosure was reported to the exchange on Feb. 11, 2026.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Lyell Immunopharma Inc | Gary Lee | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 23.39 per share. | 11 Feb 2026 | 1,671 | 16,938 | - | 23.4 | 39,085 | Common Stock |
| Lyell Immunopharma Inc | Gary Lee | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Feb 2026 | 50,000 | 50,000 | - | - | Option (right to buy) | |
| Lyell Immunopharma Inc | Gary Lee | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Feb 2026 | 4,000 | 18,756 | - | 0 | Common Stock | |
| Lyell Immunopharma Inc | Gary Lee | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 23.12 per share. | 09 Feb 2026 | 147 | 18,609 | - | 23.1 | 3,399 | Common Stock |
| Lyell Immunopharma Inc | Gary Lee | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 16.16 per share. | 10 Nov 2025 | 138 | 15,366 | - | 16.2 | 2,230 | Common Stock |
| Lyell Immunopharma Inc | Gary Lee | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Oct 2025 | 68,000 | 68,000 | - | - | Option (right to buy) | |
| Lyell Immunopharma Inc | Gary Lee | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Aug 2025 | 8,000 | 16,957 | - | 0 | Common Stock | |
| Lyell Immunopharma Inc | Gary Lee | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 10.54 per share. | 20 Aug 2025 | 1,453 | 15,504 | - | 10.5 | 15,320 | Common Stock |
| Lyell Immunopharma Inc | Gary Lee | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 10.34 per share. | 11 Aug 2025 | 136 | 8,957 | - | 10.3 | 1,406 | Common Stock |
| Lyell Immunopharma Inc | Gary Lee | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 10.53 per share. | 11 Aug 2025 | 131 | 9,093 | - | 10.5 | 1,379 | Common Stock |
| Lyell Immunopharma Inc | Gary Lee | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Feb 2025 | 450,000 | 450,000 | - | - | Option (right to buy) | |
| Lyell Immunopharma Inc | Lee Gary | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Feb 2025 | 112,500 | 176,696 | - | 0 | Common Stock | |
| Lyell Immunopharma Inc | Gary Lee | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Feb 2025 | 56,250 | 56,250 | - | - | Option (right to buy) | |
| Lyell Immunopharma Inc | Lee Gary | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Feb 2024 | 400,000 | 400,000 | - | - | Stock Option (right to buy) | |
| Lyell Immunopharma Inc | Lee Gary | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Feb 2024 | 40,000 | 52,700 | - | 0 | Common Stock | |
| Lyell Immunopharma Inc | Gary Lee | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Feb 2023 | 600,000 | 600,000 | - | - | Option (right to buy) |